Q-omics provides the consensus-scored ECT2L profile across patient tissues and cancer cell-line models. ECT2L expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, ECT2L is differentially expressed in 8, with the highest sampling consensus in LUSC. Additionally, ECT2L RNA expression shows 18,753 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, LUSC, and UVM as cancer lineages where ECT2L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ECT2L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ECT2L survival associations across molecular data types. ECT2L RNA expression shows survival associations in the most cancer types (20), followed by mutation status (7) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ECT2L RNA expression–survival associations across cancer types. High ECT2L expression shows unfavorable associations in KIRP, but favorable associations in HNSC, PAAD, THYM, BRCA and COAD. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify HNSC as the clearest survival context for ECT2L RNA expression.
This table summarizes ECT2L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for ECT2L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ECT2L shows lower tumor expression in LUSC, LUAD, UCEC and KIRP and higher tumor expression in THCA and PRAD. The LUSC box plot shows higher ECT2L RNA expression in normal versus tumor tissue (log2 FC = −1.560, t-test p < 0.001).
This table shows molecular features associated with ECT2L in patient tissues and cancer cell lines. In patient samples, ECT2L shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ECT2L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
